Kala Pharmaceuticals

Yahoo Finance • 2 months ago

KALA BIO Non-GAAP EPS of -$1.71

* KALA BIO press release [https://seekingalpha.com/pr/20194841-kala-bio-reports-second-quarter-2025-financial-results-and-provides-corporate-update] (NASDAQ:KALA [https://seekingalpha.com/symbol/KALA]): Q2 Non-GAAP EPS of -$1.71. * Cas... Full story

Yahoo Finance • 2 months ago

KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update

-- Completed patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data expected at the end of September 2025 -- -- Cash resources of $31.9 million as of June 30, 2025, expected to f... Full story

Yahoo Finance • 2 months ago

KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

ARLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe disease... Full story

Yahoo Finance • 3 months ago

Kala Bio completes enrollment in Phase 2b trial for KPI-012 in eye disorder

Kala Bio, Inc. (NASDAQ:KALA), a small-cap biotech with a market capitalization of $33.29 million, announced Wednesday the completion of patient enrollment in its CHASE Phase 2b clinical trial evaluating KPI-012, a human mesenchymal stem ce... Full story

Yahoo Finance • 3 months ago

KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

-- Topline results from the CHASE trial expected by end of Q3 2025 -- -- Potential for CHASE to serve as a pivotal trial in support of a Biologics License Application (BLA) submission, contingent on positive results -- ARLINGTON, Mass.,... Full story

Yahoo Finance • 4 months ago

KALA BIO to Present at Jefferies Global Healthcare Conference

ARLINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases... Full story

Yahoo Finance • 7 months ago

KALA BIO Announces Chief Executive Officer Transition

ARLINGTON, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe disease... Full story

Yahoo Finance • 2 years ago

KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update

-- Enrollment ongoing in CHASE Phase 2b clinical trial of KPI-012 for PCED; topline data expected in 2H 2024 -- -- As of September 30, 2023, $56.1 million in cash and cash equivalents; together with anticipated remaining funding from CIRM... Full story

Yahoo Finance • 2 years ago

KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ARLINGTON, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s Amended and Restated 2... Full story

Yahoo Finance • 2 years ago

KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference

ARLINGTON, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseas... Full story

Yahoo Finance • 2 years ago

Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ARLINGTON, Mass., June 23, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options and restricted stock units (RSUs) to new employees as inducement awards ou... Full story

Yahoo Finance • 2 years ago

Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

-- Announced positive data from initial safety portion of CHASE Phase 2b clinical trial of KPI-012; now enrolling primary safety and efficacy portion of trial, with topline data targeted in 1Q 2024 -- -- Received FDA Fast Track designatio... Full story

Yahoo Finance • 2 years ago

Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED

MENLO PARK, Calif. and ARLINGTON, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative t... Full story

Yahoo Finance • 2 years ago

Kala Pharmaceuticals Receives FDA Fast Track Designation for KPI-012, a Human MSC-S Therapy for Persistent Corneal Epithelial Defect

ARLINGTON, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and s... Full story

Yahoo Finance • 3 years ago

Kala Pharmaceuticals Appoints Dr. Francis Mah as Chief Medical Advisor

ARLINGTON, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and s... Full story

Yahoo Finance • 3 years ago

Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED

--No safety issues identified in Cohort 1 -- -- Now proceeding to Cohort 2 to evaluate the safety and efficacy of two doses of KPI-012 in a multicenter, randomized, double-masked, vehicle-controlled trial -- -- Topline data for Cohort 2 ta... Full story

Yahoo Finance • 3 years ago

Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

ARLINGTON, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and s... Full story

Yahoo Finance • 3 years ago

Kala Pharmaceuticals Stock Showing Rising Market Leadership; Earns 83 RS Rating

Kala Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 67 to 83. Continue reading... Full story

Yahoo Finance • 3 years ago

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

-- Enrolled first patient in CHASE Phase 2b clinical trial evaluating KPI-012 for PCED; Top-line data targeted for 1Q 2024 -- -- Closed $31.0 million private placement financing, extending cash runway into 1Q 2025 -- ARLINGTON, Mass., Ma... Full story

Yahoo Finance • 3 years ago

Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment

Shares of Kala Pharmaceuticals Inc. (KALA) have rocketed higher in for three-straight sessions, toward a more-than 8-fold gain, since the biopharmaceutical company announced positive news regarding its treatment of persistent corneal epith... Full story